Ultragenyx Pharmaceutical Overview
Ultragenyx Pharmaceutical Target Price
Analysts' 12-month price predictions for RARE.
Share Price
$35.98
Average Target Price
$89.50
148.7% upside
148.7% upside2 analysts in the last 4 months
High: $115 | Low: $64
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-03-17 | Piper Sandler | $115 | 219.6% upside |  |
| 2025-03-07 | Morgan Stanley | $64 | 77.9% upside | |
| 2024-11-06 | H.C. WainwrightEd Arce | $95 | 164% upside | |
| 2024-11-06 | Leerink PartnersJoseph Schwartz | $85 | 136.2% upside | |
| 2024-06-06 | Goldman SachsSalveen Richter | $67 | 86.2% upside | |
| 2024-05-31 | Stifel NicolausDae Gon Ha | $127 | 253% upside | |
| 2024-05-31 | Raymond JamesChristopher Raymond | $135 | 275.2% upside | |
| 2024-05-31 | Robert W. BairdJoel Beatty | $72 | 100.1% upside | |
| 2024-05-31 | Canaccord GenuityWhitney Ijem | $111 | 208.5% upside | |
| 2024-04-15 | Stifel NicolausDae Gon Ha | $124 | 244.6% upside | |
| 2024-04-15 | Raymond JamesChristopher Raymond | $130 | 261.3% upside | |
| 2023-02-03 | Morgan Stanley | $95 | 164% upside | |
| 2022-12-30 | H.C. Wainwright | $82 | 127.9% upside | |
| 2022-07-28 | Piper SandlerChristopher Raymond | $130 | 261.3% upside | |
| 2022-07-01 | Stifel Nicolaus | $142 | 294.7% upside | |
| 2022-05-24 | Goldman Sachs | $101 | 180.7% upside | |
| 2022-05-18 | Piper SandlerChristopher Raymond | $135 | 275.2% upside | |
| 2022-05-06 | Morgan Stanley | $109 | 202.9% upside | |
| 2022-05-06 | Leerink Partners | $115 | 219.6% upside | |
| 2022-01-10 | Cowen & Co.Yaron Werber | $124 | 244.6% upside | |
| 2021-11-03 | CitigroupYigal Nochomovitz | $150 | 316.9% upside | |
| 2021-11-03 | WedbushLaura Chico | $92 | 155.7% upside | |
| 2021-09-27 | Piper SandlerChristopher Raymond | $170 | 372.5% upside | |
| 2021-08-19 | UBSEsther Rajavelu | $73 | 102.9% upside | |
| 2021-08-03 | BarclaysGena Wang | $141 | 291.9% upside | |